How I use genomics and BTK inhibitors in the treatment of WM

Key Findings

• ●Genomics-guided treatment selection in WM
• ●MYD88 and CXCR4 genotyping informs BTK inhibitor choice
• ●MYD88-WT patients may benefit from alternative approaches

Referenced in (1 disease)